Heart failure-focused BioCardia out to grab $57M in IPO

San Carlos, CA-based BioCardia has filed an IPO designed to raise $57.5 million. The regenerative medicine biotech expects to start enrolling patients into a pivotal Phase III study for a new cell therapy for ischemic systemic heart failure later this year, with data due in 2017. Stanford Professor Simon Sterzer controls 18.5% of the stock through a family trust, the largest block of shares. CEO Peter Altman, meanwhile, controls 7.8% of the stock. S-1

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.